These findings indicate that EA exerts its therapeutic effects on stroke by regulating epigenetic changes to directly act on its targets, such as the miR-181b/PirB/RhoA/GAP43 axis, which may be a novel mechanism underlying EA treatment against ischemic stroke. Here, RHOA is linked to stroke disorder.